Rita Kalyani has left her chief scientific and medical officer role as the association continues reviewing an incident at its June meeting.
The American Diabetes Association has announced that Rita Kalyani is no longer its chief scientific and medical officer, effective immediately. The leadership change comes while the organization continues reviewing an incident at its June meeting in New Orleans. The association has said that review needs more time, leaving questions about the incident and its handling unresolved.
The announcement identifies Kalyani’s departure but gives no reason for it and does not say who will take over the role. CEO Charles Henderson thanked her for her work, saying, “We thank Dr. Kalyani for her dedication to the ADA’s mission over the years.” The notice does not link the leadership change to the ongoing review, so the timing alone does not establish that the two are connected.
That distinction matters for readers trying to understand what has changed. The confirmed information is limited: Kalyani has left her post, the association’s review is continuing, and the association has not shared further details about either a successor or the review’s conclusions. The announcement does not describe a change to the association’s scientific or medical work.
What happened at the June meeting
The organization’s current turmoil followed an event on June 5. Five members were escorted out of the meeting by armed security officers after handing out an April editorial published in the association’s journal, Diabetes Care. The editorial expressed alarm about cuts to federal research funding.
The association later said it was reviewing the incident. Just over six weeks before Kalyani’s departure was announced, it said the review would need additional time. The material available here does not explain what information the review is considering, who is conducting it, or when the association expects to report its findings. It also does not say what happened to the five members afterward.
The editorial and the meeting incident raise separate questions. The editorial’s stated concern was the effect of funding cuts on research. The incident concerns how the distribution of that editorial at the meeting was handled. The available details do not establish whether the association’s review is examining the editorial’s claims, the response to its distribution, or both.
What the leadership news does and does not tell readers
Kalyani’s title placed her among the association’s senior scientific and medical leaders, but the notice offers no further account of her responsibilities or the effect of her departure on particular programs. Without details about a successor or interim arrangements, it is too soon to draw conclusions about how the organization’s work may change.
For people who follow diabetes research or rely on the association for professional and patient information, the practical point is that a leadership departure is not itself evidence of a change in medical guidance. The announcement does not describe altered recommendations, research findings, or clinical services. Readers making health decisions should continue to look to the relevant medical evidence and discuss personal care questions with a clinician or pharmacist.
There is also a difference between knowing that an internal review continues and knowing what it has found. The association’s earlier notice confirms that more time was needed; it does not offer a conclusion about responsibility or explain why the process is taking longer. Until the organization provides more information, any account that treats Kalyani’s departure as a result of the incident would go beyond the facts available here.
What to watch next
Further clarity would depend on updates from the association: whether it names someone to fill Kalyani’s position, whether it describes the scope or outcome of its review, and whether it explains any changes to how it handles similar situations at future meetings. Those details could help members and readers assess whether the leadership transition affects the association’s scientific work or its approach to member participation.
For now, the news is a leadership change during an unresolved organizational review. The announcement provides no stated reason for Kalyani’s departure, and the review has not produced public conclusions in the material available. The next update from the association will matter more than the timing alone for understanding what this transition means.
The association’s review notice and coverage of the June incident provide further context. The departure announcement is described in Tuesday’s notice, while the April editorial sets out its concerns about research funding. Continue to STAT+ to read the full story.
